01
A potential to reduce risks of adverse events such as infection and cancer
Cytokine inhibitors, the most popular bio-therapeutics on the market, can help patients relieve symptoms associated with inflammatory diseases. However, increased risk of infection has often been noted in those inhibitors targeting immune-related cytokines such as TNF-alpha, IL-12/23, IL-6 and IL-17. Mechanistically, by targeting late-stage chronically activated T cells, our approach has the potential to reduce risks of adverse events such as infection and cancer. Accumulated clinical evidence demonstrated no signs of elevated infection risks post ALTB-168 treatment.
02
Alternative therapy for the patients who either did not respond or lost response to existing therapies
Close to 50% of RA and PsA patients treated with existing cytokine inhibitors for at least 6 months failed to achieve the 50% (ACR50) improvement criteria. Furthermore, more than 50% of patients undergoing long-term treatment of TNF-alpha inhibitors lose response to the drugs. Therefore, an alternative therapeutic agent like ALTB-168 is well positioned to treat those patients who no longer respond to or discontinue the use of these drugs.
03
A potential standard of care treatment in immunology and inflammation
Current treatments systemically suppress the immune system, leaving patients vulnerable to infection and other adverse effects. Our immune checkpoint enhancers, however, preferentially target late-stage, chronically activated T-cells with the aim to restore the immune system to a state of balance potentially providing meaningful clinical benefits to those patients with unmet medical needs.